Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 23/03/2012
PIL Lamisil Tablets 250mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/03/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change to drug interactions
Updated on 11/01/2012 and displayed until 23/03/2012
Reasons for adding or updating:
  • Change to date of revision
  • Change to storage instructions
Updated on 14/04/2011 and displayed until 11/01/2012
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 27/01/2010 and displayed until 14/04/2011
Reasons for adding or updating:
  • Change to date of revision
  • PIL Retired combination of strengths
Updated on 11/09/2009 and displayed until 27/01/2010
Reasons for adding or updating:
  • Change to side-effects
Updated on 13/02/2009 and displayed until 11/09/2009
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to side-effects
Updated on 29/01/2009 and displayed until 13/02/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 25/04/2008 and displayed until 29/01/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 30/12/2004 and displayed until 25/04/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 18/11/2003 and displayed until 30/12/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 10/06/2003 and displayed until 18/11/2003
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 24/06/2002 and displayed until 10/06/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 30/11/2001 and displayed until 24/06/2002
Reasons for adding or updating:
  • Update to PIL
Updated on 17/11/2000 and displayed until 30/11/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  terbinafine